Date: 2011-01-25

Type of information: Licensing agreement

Compound: preclinical antibody program

Company: Oxford BioTherapeutics (UK) Sanofi-Aventis (France)

Therapeutic area: Cancer - Oncology

Type agreement:


Action mechanism:

antibody drug conjugate (ADC)



sanofi-aventis has acquired an exclusive world-wide license to one of Oxford BioTherapeutics’s internal preclinical antibody programs. sanofi-aventis intends to use the licensed antibody, which is directed against a novel, proprietary target identified by OBT, to develop, manufacture and commercialize antibody drug conjugate (ADC) products for the treatment of cancer. ADC products comprise toxins attached to antibodies which form effective therapeutic products that attack tumor cells in a highly targeted manner.

Financial terms:

Under the terms of the agreement, sanofi-aventis agreed to pay OBT an undisclosed upfront cash payment. OBT is eligible for development and regulatory milestone payments on the program, royalties on the worldwide products sales and will receive additional performance milestones.

Latest news:

Is general: Yes